Professor Andrew Hughes is strategy director of the experimental cancer medicine team at The Christie. This role involves overseeing the clinical contribution to Phase 1 cancer clinical trials and a strategic growth of the research by up to 10 fold over the next 5 years. Previous to that he was Global VP of early clinical development at AstraZeneca Pharmaceuticals leading over 50 research and early clinical development programmes of novel candidate drugs. He graduated with double first in medical sciences at Cambridge, spending 3 years as a Tutor in Physiology and Bye-fellow of Downing College, Cambridge, whilst completing a PhD in behavioural neuroendocrinology in the Dept. of Anatomy. He subsequently practised general clinical medicine in Manchester’s teaching hospitals in the UK, joining Zeneca in 1994 from being a registrar in Cardiology. Within industry, he has had responsibilities on the corporate pain control drug development board and in setting the limits of human exposure based on existing pre-clinical and clinical data for all development products. Since 2001 he has been accountable for the early phase clinical development of AstraZeneca’s oncology compounds, and has been clinical investigator on over 200 clinical trials. He is approved by the Resuscitation Council (UK) as a director in Advanced Cardiac Life Support, and regularly teaches health professionals in ACLS. During 2002-3 he served on the board of the Faculty of Pharmaceutical Medicine, UK; and has the responsibility for the clinical pharmacology revision module for those physicians sitting the Diploma of Pharmaceutical Medicine. He is a former member of the board of NCRI, on the editorial committee for Annals of Oncology and on the Steering Committee for the FDA Biomarkers Consortium. In 2006, he was appointed to a chair of Translational medicine at the University of Manchester, UK. He serves on CRUK’s Biomarkers evaluation research panel, New Agents Committee and Clinical Research Committee and the NIHR EME programme. Professor Hughes serves as a board member of PCI Biotech from May 2018.
Board Member Professor Andrew Hughes, MD, PhD (born 1964)
Professor Hughes holds an MD from Cambridge, UK, and a PhD degree in behavioural neuroendocrinology. After practicing general clinical medicine in Manchester’s teaching hospitals, he joined Zeneca in 1994. He had roles of growing managerial responsibility in AstraZeneca, including Worldwide Director of Discovery Medicine; Oncology and Infection, Worldwide Clinical Head of Early Phase Oncology, and most recently Global VP of Early Clinical Development. He has been clinical investigator on over 200 clinical trials and leading over 50 research and early clinical development programmes of novel candidate drugs. Currently Professor Hughes holds a position as Strategy Director of the experimental cancer medicine at Manchester Cancer Research Centre, UK. In 2006, he was appointed to a chair of Translational medicine at the University of Manchester, UK. He became a Board member of PCI Biotech Holding ASA in May 2018.
Professor Hughes
Sitter i både styret og Scientific Advisory Committee.
Imponerende “stamtavle” med oversikt over det meste.
En person med hans bakgrunn involverer seg så sterkt i PCIB…lovende.
Lykke til
